Skip to main content
Journal cover image

Lorcaserin, a 5-HT2C agonist, decreases nicotine self-administration in female rats.

Publication ,  Journal Article
Levin, ED; Johnson, JE; Slade, S; Wells, C; Cauley, M; Petro, A; Rose, JE
Published in: J Pharmacol Exp Ther
September 2011

Lorcaserin, a selective 5-hydroxytryptamine(2C) (5-HT(2C)) agonist, has been shown to facilitate weight loss in obese populations. It was assessed for its efficacy in reducing nicotine self-administration in young adult female Sprague-Dawley rats. The effect of short-term doses (subcutaneous) on nicotine self-administration (0.03 mg/kg per infusion) with a fixed ratio 1 schedule was assessed in 3-h sessions. Short-term lorcaserin doses (0.3125-20 mg/kg) were administered in a counterbalanced order. Significant reduction of nicotine self-administration was achieved with all of the short-term doses in this range. Tests of lorcaserin on locomotor activity detected prominent sedative effects at doses greater than 1.25 mg/kg with more modest transient effects seen at 0.625 to 1.25 mg/kg. Long-term effects of lorcaserin on locomotor activity were tested with repeated injections with 0.625 mg/kg lorcaserin 10 times over 2 weeks. This low lorcaserin dose did not cause an overall change in locomotor activity relative to that of saline-injected controls. Long-term lorcaserin (0.625 mg/kg) significantly reduced nicotine self-administration over a 2-week period of repeated injections. Long-term lorcaserin at this same dose had no significant effects on food self-administration over the same 2-week period of repeated injections. These studies support development of the 5-HT(2C) agonist lorcaserin to aid tobacco smoking cessation.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Pharmacol Exp Ther

DOI

EISSN

1521-0103

Publication Date

September 2011

Volume

338

Issue

3

Start / End Page

890 / 896

Location

United States

Related Subject Headings

  • Tobacco Use Disorder
  • Smoking Cessation
  • Serotonin 5-HT2 Receptor Agonists
  • Self Administration
  • Reward
  • Receptor, Serotonin, 5-HT2C
  • Rats, Sprague-Dawley
  • Rats
  • Pharmacology & Pharmacy
  • Nicotinic Agonists
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Levin, E. D., Johnson, J. E., Slade, S., Wells, C., Cauley, M., Petro, A., & Rose, J. E. (2011). Lorcaserin, a 5-HT2C agonist, decreases nicotine self-administration in female rats. J Pharmacol Exp Ther, 338(3), 890–896. https://doi.org/10.1124/jpet.111.183525
Levin, Edward D., Joshua E. Johnson, Susan Slade, Corinne Wells, Marty Cauley, Ann Petro, and Jed E. Rose. “Lorcaserin, a 5-HT2C agonist, decreases nicotine self-administration in female rats.J Pharmacol Exp Ther 338, no. 3 (September 2011): 890–96. https://doi.org/10.1124/jpet.111.183525.
Levin ED, Johnson JE, Slade S, Wells C, Cauley M, Petro A, et al. Lorcaserin, a 5-HT2C agonist, decreases nicotine self-administration in female rats. J Pharmacol Exp Ther. 2011 Sep;338(3):890–6.
Levin, Edward D., et al. “Lorcaserin, a 5-HT2C agonist, decreases nicotine self-administration in female rats.J Pharmacol Exp Ther, vol. 338, no. 3, Sept. 2011, pp. 890–96. Pubmed, doi:10.1124/jpet.111.183525.
Levin ED, Johnson JE, Slade S, Wells C, Cauley M, Petro A, Rose JE. Lorcaserin, a 5-HT2C agonist, decreases nicotine self-administration in female rats. J Pharmacol Exp Ther. 2011 Sep;338(3):890–896.
Journal cover image

Published In

J Pharmacol Exp Ther

DOI

EISSN

1521-0103

Publication Date

September 2011

Volume

338

Issue

3

Start / End Page

890 / 896

Location

United States

Related Subject Headings

  • Tobacco Use Disorder
  • Smoking Cessation
  • Serotonin 5-HT2 Receptor Agonists
  • Self Administration
  • Reward
  • Receptor, Serotonin, 5-HT2C
  • Rats, Sprague-Dawley
  • Rats
  • Pharmacology & Pharmacy
  • Nicotinic Agonists